Oak Grove Capital’s AbbVie ABBV Stock Holding History

Oak Grove Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,970	Closed	-$473K	–	56
2023 Q1	$473K	Sell	2,970 -69,278	-96%	-$10.6M	0.19%	39
2022 Q4	$11.7M	Sell	72,248 -42,593	-37%	-$6.53M	5.87%	5
2022 Q3	$15.4M	Sell	114,841 -3,300	-3%	-$474K	5.2%	5
2022 Q2	$18.1M	Sell	118,141 -25,165	-18%	-$3.85M	5.88%	4
2022 Q1	$23.2M	Sell	143,306 -2,210	-2%	-$321K	4.71%	6
2021 Q4	$19.7M	Sell	145,516 -13,099	-8%	-$1.55M	3.43%	9
2021 Q3	$17.1M	Sell	158,615 -1,255	-0.8%	-$143K	3.69%	9
2021 Q2	$18M	Buy	159,870 +31,000	+24%	+$3.49M	4.03%	5
2021 Q1	$13.9M	Buy	128,870 +34,114	+36%	+$3.65M	3.89%	6
2020 Q4	$10.2M	Buy	94,756 +23,731	+33%	+$2.28M	3.32%	6
2020 Q3	$6.22M	Buy	71,025 +56,657	+394%	+$5.33M	2.94%	12
2020 Q2	$1.41M	Sell	14,368 -26,300	-65%	-$2.32M	0.85%	27
2020 Q1	$3.1M	Sell	40,668 -2,254	-5%	-$192K	2%	18
2019 Q4	$3.8M	Buy	42,922 +39,422	+1,126%	+$3.27M	1.48%	24
2019 Q3	$265K	Buy	+3,500	New	+$240K	0.12%	67
2018 Q4	–	Sell	-850	Closed	-$80K	–	61
2018 Q3	$80K	Buy	850 +350	+70%	+$33.2K	0.07%	67
2018 Q2	$46K	Hold	500	–	–	0.05%	68
2018 Q1	$47K	Buy	+500	New	+$54.9K	0.05%	71

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oak Grove Capital's ABBV Position: Q2 2023 in Review

Oak Grove Capital sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 2,970 shares — an estimated $473K sold.

Oak Grove Capital first reported a position in ABBV in Q1 2018 and held it in 18 quarters. The position peaked at $23.2M in Q1 2022. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Oak Grove Capital reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
Oak Grove Capital sold 2,970 AbbVie shares in Q2 2023, an estimated $473K.
Oak Grove Capital first reported a position in AbbVie in Q1 2018 and held it in 18 quarters.
Oak Grove Capital's AbbVie position peaked at $23.2M in Q1 2022.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Oak Grove Capital's 13F filing for Q2 2023, filed 7 Aug 2023.